Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics

Core Insights - Travere Therapeutics reported a revenue of $74.79 million for Q4 2024, marking a 66% year-over-year increase and exceeding the Zacks Consensus Estimate of $73.44 million by 1.84% [1] - The company posted an EPS of -$0.73, an improvement from -$1.16 a year ago, but fell short of the consensus estimate of -$0.58, resulting in an EPS surprise of -25.86% [1] Revenue Breakdown - Revenue from Tiopronin products (Thiola) was $23.90 million, slightly below the estimated $24.03 million, reflecting a year-over-year decrease of 5.2% [4] - Total net product sales reached $73.55 million, surpassing the estimated $69.22 million [4] - Revenue from FILSPARI was $49.64 million, significantly exceeding the estimated $45.31 million, representing a remarkable year-over-year increase of 237.7% [4] - License and collaboration revenue was reported at $1.24 million, falling short of the average estimate of $4.77 million, indicating a year-over-year decline of 75.9% [4] Stock Performance - Over the past month, Travere's shares have returned +19.9%, outperforming the Zacks S&P 500 composite's +2.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]